The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Cancers and multiple sclerosis: risk of comorbidity and influence of disease modifying therapy

Authors:

Boĭko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2‑2): 86‑93

DOI: 10.17116/jnevro20191192286

Views: 5192

Downloaded: 112

Download PDF (RU)
Contact the author
Table of contents

CANCERS AND MULTIPLE SCLEROSIS: RISK OF COMORBIDITY AND INFLUENCE OF DISEASE MODIFYING THERAPY
CANCERS AND MULTIPLE SCLEROSIS: RISK OF COMORBIDITY AND INFLUENCE OF DISEASE MODIFYING THERAPY

To cite this article:

Boĭko AN. Cancers and multiple sclerosis: risk of comorbidity and influence of disease modifying therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2‑2):86‑93. (In Russ.)
https://doi.org/10.17116/jnevro20191192286

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Close metadata
Recommended articles:
Sleep diso­rders during pregnancy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):99-104
Sleep diso­rders and onco­logical diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):125-131
Use of systemic steroids in hospitalized patients with COVID-19. Russian Journal of Preventive Medi­cine. 2024;(5):75-80
Our expe­rience in the treatment of congenital nasal median hete­rotopias in children and an overview of various treatment tactics. Russian Bulletin of Otorhinolaryngology. 2024;(2):28-32
Clinical and anatomical rationale for the effe­ctiveness of treatment of phle­gmon of the floor of the oral cavity and deep cellular spaces of the neck complicated with sepsis. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(2):19-25
A role of cere­brovascular diseases in the progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):53-57
B vita­mins and diseases of the peri­pheral nervous system. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):75-82
Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137
Expe­rience with the use of risdiplam in a fami­lial case of spinal muscular atro­phy 5q in patients with a homo­zygous dele­tion of the SMN1 gene and the same copy number of the SMN2 gene. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):138-141
Rela­tionship between pregnancy and the risk of mali­gnant neoplasms of the female reproductive system. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):48-54

Data of clinical-epidemiological studies on the risk of cancer in patients with multiple sclerosis (MS) are discussed. A trend towards increased risks of brain tumors and urological cancers has been shown. The author considers risk factors, including disease modifying therapies (DMT), for different cancers. It has been concluded that longitudinal observational and large cohort studies along with MS registers are needed to clarify a role of DMD in the development of malignant neoplasms.

Keywords:

multiple sclerosis
cancer
DMT

Authors:

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

List of references:

  1. Lunde HMB, Assmus J, Myhr KM, Bø L, Grytten N Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017;88(8):621-625. https://doi.org/10.1136/jnnp-2016-315238
  2. Velazquez Berumen A, Jimenez Moyao G, Rodriguez NM, Ilbawi AM, Migliore A, Shulman LN. Defining priority medical devices for cancer management: a WHO initiative. Lancet Oncol. 2018;19(12):709-719. https://doi.org/10.1016/S1470-2045(18)30658-2
  3. Nielsen NM, Rostgaard K, Rasmussen S, Koch-Henriksen N, Storm HH, Melbye M, Hjalgrim H. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer. 2006;118:979-984. https://doi.org/10.1002/ijc.21437
  4. Midgard R, Glattre E, Gronning M, Riise T, Edland A, Nyland H. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand. 1996;93:411-415.
  5. Sumelahti M-L, Pukkala E, Hakama M. Cancer incidence in multiple sclerosis: a 35-year follow-up. Neuroepidemiology. 2004;23:224-227.
  6. Goldacre MJ, Seagroatt V, Yeates D, Acheson ED. Skin cancer in people with multiple sclerosis: a record linkage study. J Epidemiol Community Health. 2004;58:142-144.
  7. Achiron A, Barak Y, Gail M, Mandel M, Pee D, Ayyagari R, Rotstein Z. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat. 2005;89:265-270. https://doi.org/10.1007/s10549-004-2229-4
  8. Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T. Cancer risk among patients with multiple sclerosis and their parents. Neurology. 2009;72:1170-1177. https://doi.org/10.1212/01.wnl.0000345366.10455.62
  9. Lebrun C, Debouverie M, Vermersch P, Clavelou P, Rumbach L, de Seze J, Wiertlevski S, Defer G, Gout O, Berthier F, Danzon A. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. 2008;14:399-405. https://doi.org/10.1177/1352458507083625
  10. Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J, Hashimoto S, Tremlett H. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain. 2012;135:2973-2979. https://doi.org/10.1093/brain/aws148
  11. Sun LM, Lin CL, Chung CJ, Liang JA, Sung FC, Kao CH. Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study. Eur J Neurol. 2014;21:238-244.
  12. Moisset X, Perié M, Pereira B, Dumont E, Lebrun-Frenay C, Lesage FX, Dutheil F, Taithe F, Clavelou P. Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study. PLoS One. 2017;12(11): e0188120. https://doi.org/10.1371/journal.pone.0188120
  13. Kyritsis AP, Boussios S, Pavlidis N. Cancer specific risk in multiple sclerosis patients. Crit Rev Oncol Hematol. 2016;98:29-34.
  14. Marrie RA, Cohen J, Stuve O, Trojano M, Sørensen PS, Reingold S, Cutter G, Reider N. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Mult Scler J. 2015;3:294-304. https://doi.org/10.1177/1352458514564489
  15. Stroet A, Hemmelmann C, Starck M, Zettl U, Dörr J, Friedemann P, Flachenecker P, Fleischer V, Zipp F, Nückel H, Kieseier BC, Ziegler A, Gold R, Chan A. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord. 2012;5:75-79. https://doi.org/10.1177/1756285611433318
  16. Ragonese P, Aridon P, Salemi G, D’Amelio M, Savettieri G. Answer to: the possible risk of cancer in multiple sclerosis patients: a controversial issue. Eur J Neurol. 2011;18:e50. https://doi.org/10.1111/j.1468-1331.2010.03304.x
  17. Le Bouc R, Zéphir H, Majed B, Vérier A, Marcel M, Vermersch P. No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis. Mult Scler. 2012;18:55-63. https://doi.org/10.1177/1352458511416839
  18. Portaccio E, Zipoli V, Siracusa G, Piacentini S, Sorbi S, Amato MP. Safety and tolerability of cyclophosphamide ‘pulses’ in multiple sclerosis: A prospective study in a clinical cohort. Mult Scler. 2003;9(5):446-450.
  19. Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A, Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Trojano M, Mancardi GL, Bergamaschi R, Gasperini C, Rodegher M, Straffi L, Ponzio M, Comi G. Italian Mitoxantrone Group. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology. 2011;77:1887-1895. https://doi.org/10.1212/WNL.0b013e318238ee00
  20. Buttmann M, Seuffert L, Mäder U, Toyka KV. Malignancies after mitoxantrone for multiple sclerosis: a retrospective cohort study. Neurology. 2016;86(23):2203-2207. https://doi.org/10.1212/WNL.0000000000002745
  21. Doosti R, Togha M, Moghadasi AN, Aghsaie A, Azimi AR, Khorramnia S, Moinfar Z, Ensani F, Harirchian MH, Minagar A, Sahraian MA. Evaluation of the risk of cervical cancer in patients with Multiple Sclerosis treated with cytotoxic agents: A cohort study Iran. J Neurol. 2018;17(2):64-70.
  22. Ragonese P, Aridon P, Vazzoler G, Mazzola MA, Lo Re V, Lo Re M, Realmuto S, Alessi S, D’Amelio M, Savettieri G, Salemi G. Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study. BMC Neurol. 2017;17(1):155. https://doi.org/10.1186/s12883-017-0932-0
  23. Boneschi FM, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;(5):CD002127. https://doi.org/10.1002/14651858.CD002127.pub3
  24. Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H. Assessment of cancer risk with β-interferon treatment for multiple sclerosis. J Neurol Neurosurg Psychiatr. 2014;85:1096-1102. https://doi.org/10.1136/jnnp-2013-307238
  25. Bloomgren G, Sperling B, Cushing K, Wenten M. Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data. Ther Clin Risk Manag. 2012;8:313-321.
  26. de Jong HJI, Kingwell E, Shirani A, Cohen Tervaert JW, Hupperts R, Zhao Y, Zhu F, Evans C, van der Kop ML, Traboulsee A, Gustafson P, Petkau J, Marrie RA, Tremlett H. Evaluating the safety of β-interferons in MS: A series of nested case-control studies. Neurology. 2017;88(24):2310-2320. https://doi.org/10.1212/WNL.0000000000004037
  27. Sandberg-Wollheim M, Kornmann G, Bischof D, Moraga M, Hennessy B, Alteri E. The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings. Mult Scler. 2011;17:431-440.
  28. Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74:1463-1470. https://doi.org/10.1212/WNL.0b013e3181dc1ae0
  29. Gusev EI, Zavalishin IA, Boyko AN. Multiple sclerosis. Clinical quideline. M.: Real-taim; 2011. (In Russ.)
  30. Sadiq SA, Rammal M, Sara G. Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS. Mult Scler. 2008;14(2):272-273.
  31. Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev. 2007;4:CD003982.
  32. Melendez-Torres GJ, Armoiry X, Court R, Patterson J, Kan A, Auguste P, Madan J, Counsell C, Ciccarelli O, Clarke A. Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages. BMC Neurol. 2018;18(1):162. https://doi.org/10.1186/s12883-018-1162-9
  33. Boyko A. Long-term results of the first line DMT depend on the presence of minimal MS activity during first years of therapy: data of 15 years observation. Multiple Sclerosis & Demyelinating Diseases. 2016:1:14. https://doi.org/10.1186/s40893-016-0015-x
  34. Järvinen E, Holmberg M, Sumelahti M-L. Injectable Disease Modifying Agents in Multiple Sclerosis: Pattern of Medication Use and Clinical Effectiveness. Neurol Int. 2016;8(3):6513. https://doi.org/10.4081/ni.2016.6513
  35. Boyko AN, Gusev EI. Current algorithms of diagnosis and treatment of multiple sclerosis based on the individual assessment of the patient. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017; 117(2/2):92-106. https://doi.org/10.17116/jnevro20171172292-106 (In Russ.)
  36. Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D, Chataway J, Schmierer K. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflammation. 2015;2(6):e158. https://doi.org/10.1212/NXI.0000000000000158
  37. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234. https://doi.org/10.1056/NEJMoa1601277
  38. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209-220. https://doi.org/10.1056/NEJMoa1606468
  39. Hauser S, Kappos L, Montalban X, Koendgen H, Li C, Marcillat C, Pradhan A, Wormser D, Wolinsky J. Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis. Presented at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Berlin, Germany. Poster P1229. Neurology. 2018;90:15.
  40. Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ; CLARITY Study Group Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbineTablets treating multiple sclerosis orallY) study. Mult Scler. 2011;17(5):578-593. https://doi.org/10.1177/1352458510391344
  41. Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594-1604. https://doi.org/10.1177/1352458517727603
  42. Deeks ED. Cladribine tablets: A review in relapsing MS. CNS Drugs. 2018;32(8):785-796. https://doi.org/10.1007/s40263-018-0562-0
  43. Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler. 2018;24(11):1461-1468. https://doi.org/10.1177/1352458517726380
  44. Gaindh D, Kavak KS, Teter B, Vaughn CB, Cookfair D, Hahn T, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. J Neurol Sci. 2016;370:13-17. https://doi.org/10.1016/j.jns.2016.09.005.
  45. Huang O, Zhang W, Zhi Q, Xue X, Liu H, Shen D, Geng M, Xie Z, Jiang M. Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells. Exp Biol Med. 2015;240(4):426-437. https://doi.org/10.1177/1535370214554881
  46. Xie X, Zhao Y, Ma CY, Xu XM, Zhang YQ, Wang CG, Jin J, Shen X, Gao JL, Li N, Sun ZJ, Dong DL. Dimethyl fumarate induces necroptosis in colon cancer cells through glutathione depletion/ROS increase/MAPKs activation pathway. Br J Pharmacol. 2015;172:3929-3943. https://doi.org/10.1111/bph.13184
  47. White C, Alshaker H, Cooper C, Winkler M, Pchejetski D. The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget. 2016;7(17):23106-23127. https://doi.org/10.18632/oncotarget.7145
  48. Landais A, Alhendi R, Gouverneur A, Teron-Aboud B. A case of lymphoma in a patient on teriflunomide treatment for relapsing MS. Mult Scler Relat Disord. 2017;17:92-94. https://doi.org/10.1016/j.msard.2017.07.001
  49. Cohan S, Godwin J, Gaedeke L. Acute lymphoblastic leukemia in a man treated with fingolimod for relapsing MS. J Investig Med High Impact Case Rep. 2015;3(1):2324709615575551. https://doi.org/10.1177/2324709615575551
  50. Stitt DW, Boes CJ, Flanagan EP, Howard MT, Colgan JP. A case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod. Mult Scler Relat Disord. 2018;19:115-117. https://doi.org/10.1016/j.msard.2017.11.014
  51. Killestein J, Leurs CE, Hoogervorst ELJ, van Eijk J, Mostert JP, van den Eertwegh AJM, Uitdehaag BMJ. Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS. Neurology. 2017;89(9):970-972. https://doi.org/10.1212/WNL.0000000000004293
  52. Pace AA, Zajicek JP. Melanoma following treatment with alemtuzumab for MS. Eur J Neurol. 2009;16(4):70-71. https://doi.org/10.1111/j.1468-1331.2009.02552.x
  53. Yaldizli O, Baumberger P, Putzki N. Natalizumab and atypical naevi: Comments on the pharmacovigilance. Ann Dermatol Venereol. 2009;136:450-451. https://doi.org/10.1016/j.annder.2009.03.018
  54. Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med. 2008;358:647-648. https://doi.org/10.1056/NEJMc0706103
  55. Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult Scler. 2009;15(12):1532-1533. https://doi.org/10.1177/1352458509347154
  56. Vavricka BM, Baumberger P, Russmann S, Kullak-Ublick GA. Diagnosis of melanoma under concomitant natalizumab therapy. Mult Scler. 2011;17:255-256. https://doi.org/10.1177/1352458510389629
  57. Laroni A, Bedognetti M, Uccelli A, Capello E, Mancardi GL. Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurol Sci. 2011;32:181-182. https://doi.org/10.1007/s10072-010-0427-x
  58. Ismail A, Kemp J, Sharrack B. Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis. J Neurol. 2009;256:1771-1772. https://doi.org/10.1007/s00415-009-5200-9
  59. Rommer PS, Zettl UK. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. Expert Opin Pharmacother. 2018;19(5):483-498. https://doi.org/10.1080/14656566.2018.1446944
  60. Sabol RA, Noxon V, Sartor O, Berger JR, Qureshi Z, Raisch DW, Norris LB, Yarnold PR, Georgantopoulos P, Hrushesky WJ, Bobolts L, Ray P, Lebby A, Kane RC, Bennett CL. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). Cancer Med. 2017;6(7):1541-1551. https://doi.org/10.1002/cam4.1098
  61. Catalá‐López F, Suárez‐Pinilla M, Suárez‐Pinilla P, Valderas JM, Gómez-Beneyto M, Martinez S, Balanzá-Martínez V, Climent J, Valencia A, McGrath J, Crespo-Facorro B, Sanchez-Moreno J, Vieta E, Tabarés-Seisdedos R. Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta‐analysis of cancer incidence in 577.013 participants of 50 observational studies. Psychother Psychosom. 2014;83:89-105. https://doi.org/10.1159/000356498
  62. Capkun G, Dahlke F, Lahoz R, Nordstrom B, Tilson HH, Cutter G, Bischof D, Moore A, Simeone J, Fraeman K, Bancken F, Geissbühler Y, Wagner M, Cohan S. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of Defense administrative claims database. Mult Scler Relat Disord. 2015;4:546-554. https://doi.org/10.1016/j.msard.2015.08.005
  63. Tysabri risk minimization action plan: summary of TOUCH. FDA; 2015. http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm107197.pdf
  64. Pharaon M, Tichet M, Lebrun‐Frenay C, Tartare‐Deckert S, Passeron T. Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow‐up with immunohistological studies and proliferation and invasion assays. JAMA Dermatol. 2014;150:901-903. https://doi.org/10.1001/jamadermatol.2013.9411
  65. Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 2005;24:195-222.
  66. Lebrun C, Rocher F. Cancer risk in patients with multiple sclerosis: Potential Impact of Disease-Modifying Drugs. CNS Drugs. 2018;32(10):939-949. https://doi.org/10.1007/s40263-018-0564-y

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.